#1
|
||||
|
||||
Ñïèñîê ëåê. ñðåäñòâ ñ íåäîêàçàííîé ýôôåêòèâíîñòüþ
Óâàæàåìûå êîëëåãè!
Ïîäñêàæèòå, ãäå íàéòè òàêîé ñïèñîê. Âîò çäåñü åñòü, íî íåìíîãî íåáðåæíî, õîòåëîñü áû ïîëíåå, ñ îáîñíîâàíèåì: [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] |
#2
|
||||
|
||||
Íó â ýòîì ñïèñêå êàê ðàç íå âñå ïðàâäà. Ãåïòðàë è ðàñòîðîïøà(ëåãàëîí-140), íàïðèìåð, êàê ðàç âïîëíå íîðìàëüíûå ïðåïàðàòû.
__________________
Ñ óâàæåíèåì, Þñèô Àëõàçîâ. |
#3
|
|||
|
|||
Ìíå êàæåòñÿ, ÷òî ìû óæå íåîäíîêðàòíî îáñóæäàëè ïîäîáíûé "îáùèé" âîïðîñ. Íà íåãî íåëüçÿ äàòü êîíêðåòíûé, îäíîçíà÷íûé è îáùèé îòâåò, ïîòîìó ÷òî ýôôåêòèâíîñòü è áåçîïàñíîñòü ëåêàðñòâåííûõ ñðåäñòâ íå áûâàåò âîîáùå, à áûâàåò òîëüêî äëÿ îïðåäåëåííîé ïîïóëÿöèè ïàöèåíòîâ ñ îïðåäåëåííîé ïàòîëîãèåé.
|
#4
|
||||
|
||||
Öèòàòà:
Èëè ÿ Âàñ íåïðàâèëüíî ïîíÿë? |
#5
|
|||
|
|||
Öèòàòà:
Ò.å. íåâîçìîæíî ãîâîðèòü î íåýôôåêòèâíîñòè èíòåðôåðîíà-àëüôà-2 âîîáùå. |
#6
|
||||
|
||||
Öèòàòà:
ß âñåãî íàâñåãî äèàãíîñò, íî è ìåíÿ èíîãäà ïàöèåíòû ñïðàøèâàþò îá ýôôåêòèâíîñòè íåêîòîðûõ ïðåïàðàòîâ. Êðîìå òîãî, ìíå ýòî èíòåðåñíî, ò.ê. èíîãäà ïðè ïîâòîðíûõ èññëåäîâàíèÿõ ÿ ó÷àñòâóþ â îöåíêå ýôôåêòà ëå÷åíèÿ. |
#7
|
|||
|
|||
Öèòàòà:
|
|
#8
|
||||
|
||||
Ïðî íåéðîïðîòåêòîðû - â ðàçäåëå íåâðîëîãèÿ, ñ îáîñíîâàíèåì è äèñêóññèåé.
|
#9
|
||||
|
||||
Ïî ïðåäóêòàëó êàê ðàç äîêàçàòåëüñòâà åñòü, òîëüêî ñëàáåíüêèé îí...
|
#10
|
||||
|
||||
Âîò íàø¸ë áîëüøîé òåêñò - 267 ïðåïàðàòîâ!
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] |
#11
|
||||
|
||||
Âñ¸ íèàñèëèë, íî òî, ÷òî åñòü - èíîãäà î÷åíü ñïîðíî... íàïðèìåð:
Öèòàòà:
Öèòàòà:
Öèòàòà:
Öèòàòà:
|
#12
|
|||
|
|||
Î÷åíü ñòðàííî, ÷òî â ýòîò ñïèñîê ïîïàëè Êåïïðà è Äåïàêèí Õðîíî (íîìåð 117). Âàëüïðîåâàÿ êèñëîòà(Äåïàêèí, Êîíâóëåêñ, Êóíâóëüñîôèí) - ýòî óíèâåðñàëüíîå ïðîòèâîýïèëåïòè÷åñêîå ñðåäñòâî, ýôôåêòèâíî èñïîëüçóþùååñÿ ïðè ýïèëåïñèè ñ 60-õ ãîäîâ XX âåêà. Î äîêàçàòåëüíîé áàçå äàæå ñìåøíî ãîâîðèòü... Òûñÿ÷è èññëåäîâàíèé è òîííû ëèòåðàòóðû.  ïñèõèàòðèè âàëüïðîåâàÿ êèñëîòà îáîñíîâàííî ïðèìåíÿåòñÿ â êà÷åñòâå íîðìîòèìè÷åñêîãî ñðåäñòâà ïðè ðàññòðîéñòâàõ àôôåêòà. ×òî æå êàñàåòñÿ ïðåïàðàòà Êåïïðà(ëåâåòèðàöåòàì), òî ýòî îäíî èç ñðàâíèòåëüíî íîâûõ ïðîòèâîýïèëåïòè÷åñêèõ ñðåäñòâ, çàðåãèñòðèðîâàííîå â ÑØÀ â 1999 ãîäó (ó íàñ - â 2003 ãîäó) è îáëàäàþùåå íå òîëüêî õîðîøåé ïåðåíîñèìîñòüþ, íî è è ðÿäîì âàæíåéøèõ ïðåèìóùåñòâ, çíà÷èòåëüíî ðàñøèðÿþùèõ åãî êëèíè÷åñêîå ïðèìåíåíèå ïðè ýïèëåïñèè.
|
#13
|
||||
|
||||
Öèòàòà:
Çà÷åì òàê ìíîãî âîçìóùåíèé? Ïðîñòî, ïîæàëóéñòà, äàéòå ññûëêè íà ïîñëåäíèå ãàéäû è èñïûòàíèÿ ñ ýòèìè ïðåïàðàòàìè. |
#14
|
|||
|
|||
Åùå îäèí ïîäîáíûé ñïèñîê [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
|
#15
|
|||
|
|||
Öèòàòà:
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] (Levetiracetam*for partial seizures: results of a double-blind, randomized clinical trial). [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] (Multicenter double-blind, randomized, placebo-controlled trial of*levetiracetam*as add-on therapy in patients with refractory partial seizures. European*Levetiracetam*Study Group) [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] (Efficacy and tolerability of*levetiracetam*3000 mg/d in patients with refractory partial seizures: a*multicenter,double-blind, responder-selected study evaluating monotherapy. European*Levetiracetam*Study Group). [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] (Efficacy and safety of*levetiracetam*(up to 2000 mg/day) in Taiwanese patients with refractory partial seizures: amulticenter,*randomized,*double-blind,*placebo-controlled*study). [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] (Once-daily extended-release*levetiracetam*as adjunctive treatment of partial-onset seizures in patients with epilepsy: a*double-blind,*randomized,*placebo-controlled*trial). Èññëåäîâàíèÿ ïî ýôôåêòèâíîñòè ëåâåòèðàöåòàìà â ïåäèàòðè÷åñêîé ïðàêòèêå: [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] (Double-blind*placebo-controlled*trial*of adjunctive*levetiracetam*in pediatric partial seizures). [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] (Adjunctive*levetiracetam*in infants and young children with refractory partial-onset seizures). [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] (Levetiracetam*as add-on therapy for idiopathic generalized epilepsy syndromes with onset during adolescence: analysis of two*randomized,*double-blind,*placebo-controlled*studies). Èññëåäîâàíèå ïî íàëè÷èþ ïîëîæèòåëüíîãî íåéðîêîãíèòèâíîãî ýôôåêòà ó ëåâåòèðàöåòàìà: [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] (Neurocognitive effects of adjunctive*levetiracetam*in children with partial-onset seizures: a*randomized,*double-blind,*placebo-controlled, noninferiority*trial). Åñòåñòâåííî, ÿ ïðèâ¸ë äàëåêî íå âñå èññëåäîâàíèÿ, äîêàçûâàþùèå ýôôåêòèâíîñòü ëåâåòèðàöåòàìà ïðè ýïèëåïñèè. |